Adult neurogenesis augmentation attenuates anhedonia and HPA axis dysregulation in a mouse model of chronic stress and depression.
Adult Hippocampal neurogenesis
Anhedonia
Depression
Glucocorticoids
HPA axis
Stress
Journal
Psychoneuroendocrinology
ISSN: 1873-3360
Titre abrégé: Psychoneuroendocrinology
Pays: England
ID NLM: 7612148
Informations de publication
Date de publication:
02 2021
02 2021
Historique:
received:
24
07
2020
revised:
06
11
2020
accepted:
26
11
2020
pubmed:
11
12
2020
medline:
1
2
2022
entrez:
10
12
2020
Statut:
ppublish
Résumé
Major depressive disorder is a common debilitating mental health problem that represents one of the leading causes of disability. Up to date, the therapeutic targets and approaches are still limited. Adult hippocampal neurogenesis (AHN) has been proposed as a critical contributor to the pathophysiology and treatment of depression, altering the hippocampal control over stress response at network, neuroendocrine and behavioral levels. These findings together have suggested that manipulating AHN may be a promising therapeutic strategy for depression. To investigate this question, we assessed whether increasing adult neurogenesis would be sufficient to produce antidepressant-like effects at behavioral and neuroendocrine levels in a mouse model of depression; the unpredictable chronic mild stress (UCMS). For this purpose, we used a bi-transgenic mouse line (iBax) in which AHN increase was induced by deletion of the pro-apoptotic gene Bax from the neural progenitors following the tamoxifen-dependent action of CreERT2 recombinases. UCMS induced a syndrome that is reminiscent of depression-like states, including anhedonia (cookie test), physical changes (coat deterioration, reduced weight gain), anxiety-like behaviors (higher latency in the novelty-supressed feeding -NSF- test), passive stress-coping behaviors (immobility in the forced swim test -FST-) and a blunted hypothalamo-pituitary-adrenal (HPA) axis reactivity to acute stress in addition to AHN decrease. Tamoxifen injection reversed the AHN decrease as well as partly counteracted UCMS effects on the cookie test and HPA axis but not for the coat state, weight gain, NSF test and FST. Taken together, our results suggest that a strategy directing at increasing AHN may be able to alleviate some depression-related behavioral and neuroendocrine dimensions of UCMS, such as anhedonia and HPA axis reactivity deficits, but may be hardly sufficient to produce a complete recovery.
Identifiants
pubmed: 33302237
pii: S0306-4530(20)30520-5
doi: 10.1016/j.psyneuen.2020.105097
pmc: PMC8715720
mid: NIHMS1757279
pii:
doi:
Substances chimiques
Tamoxifen
094ZI81Y45
Corticosterone
W980KJ009P
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
105097Subventions
Organisme : NIMH NIH HHS
ID : R01 MH068542
Pays : United States
Organisme : NIMH NIH HHS
ID : R37 MH068542
Pays : United States
Informations de copyright
Copyright © 2020 Elsevier Ltd. All rights reserved.
Références
Cell Stem Cell. 2015 Oct 1;17(4):385-95
pubmed: 26431181
Nature. 2006 Aug 24;442(7105):929-33
pubmed: 16906136
Psychoneuroendocrinology. 2008 Nov;33(10):1357-68
pubmed: 18790573
Curr Protoc Neurosci. 2001 May;Chapter 8:Unit 8.10A
pubmed: 18428536
Neuroscience. 2003;119(3):887-97
pubmed: 12809708
Science. 2015 May 1;348(6234):560-3
pubmed: 25931556
Hippocampus. 2012 Jan;22(1):106-16
pubmed: 20882540
Cell Death Differ. 2014 Feb;21(2):196-205
pubmed: 24162660
Am J Psychiatry. 2000 Jan;157(1):115-8
pubmed: 10618023
PLoS One. 2010 Apr 28;5(4):e10404
pubmed: 20436931
Front Neural Circuits. 2013 Dec 26;7:204
pubmed: 24421758
Biochem Pharmacol. 2017 Oct 1;141:86-99
pubmed: 28800956
Trends Pharmacol Sci. 2008 Oct;29(10):493-8
pubmed: 18755516
Neuropsychopharmacology. 2015 Sep;40(10):2368-78
pubmed: 25833129
Neuron. 2009 May 28;62(4):479-93
pubmed: 19477151
Science. 2017 Jan 13;355(6321):176-180
pubmed: 28082589
J Neurosci. 2007 Jan 17;27(3):472-82
pubmed: 17234580
Neuron. 2018 Jul 11;99(1):179-193.e7
pubmed: 30008297
Proc Natl Acad Sci U S A. 2014 Sep 30;111(39):E4076-85
pubmed: 25228770
J Neurosci. 1989 Sep;9(9):3072-82
pubmed: 2795152
Behav Brain Res. 2000 Oct;115(1):95-106
pubmed: 10996412
J Neurosci. 2008 Feb 6;28(6):1374-84
pubmed: 18256257
Biomed Res Int. 2013;2013:868742
pubmed: 23533999
Pharmacol Biochem Behav. 2001 Oct-Nov;70(2-3):187-92
pubmed: 11701187
Neuroscience. 2003;117(4):1025-35
pubmed: 12654354
Behav Brain Res. 2005 Nov 7;164(2):266-9
pubmed: 16087251
Curr Protoc Pharmacol. 2013 Jun;Chapter 5:Unit 5.65
pubmed: 23744712
Brain Res Mol Brain Res. 2004 Apr 7;123(1-2):112-20
pubmed: 15046872
Neuropharmacology. 2017 Nov;126:179-189
pubmed: 28890366
Proc Natl Acad Sci U S A. 2019 Feb 12;116(7):2733-2742
pubmed: 30683720
Nature. 2018 Dec;564(7735):258-262
pubmed: 30478293
Nature. 2011 Aug 03;476(7361):458-61
pubmed: 21814201
Neuropsychopharmacology. 2009 May;34(6):1363-80
pubmed: 18536703
Nat Rev Neurosci. 2000 Dec;1(3):191-8
pubmed: 11257907
Endocrinology. 2015 Aug;156(8):2843-53
pubmed: 26046806
Front Behav Neurosci. 2013 Aug 08;7:61
pubmed: 23964212
Neuron. 2020 Jul 8;107(1):173-184.e6
pubmed: 32359400
Compr Physiol. 2016 Mar 15;6(2):603-21
pubmed: 27065163
Transl Psychiatry. 2017 Apr 25;7(4):e1101
pubmed: 28440814
Nat Neurosci. 2010 Aug;13(8):995-1002
pubmed: 20639874
Psychoneuroendocrinology. 2017 Jun;80:137-146
pubmed: 28343139
Psychopharmacology (Berl). 1985;85(3):367-70
pubmed: 3923523
Brain Res. 1971 Nov;34(1):171-5
pubmed: 5124915
Hippocampus. 2012 Feb;22(2):359-71
pubmed: 21184481
Biol Psychiatry. 2008 Aug 15;64(4):293-301
pubmed: 18406399
Nature. 2018 Jul;559(7712):98-102
pubmed: 29950730
Science. 2019 May 10;364(6440):578-583
pubmed: 31073064
Neuroimage. 2004 May;22(1):409-18
pubmed: 15110034
Neuron. 2016 Apr 6;90(1):101-12
pubmed: 26971949
Neurosci Res. 2018 Sep;134:56-60
pubmed: 29246683
Mol Psychiatry. 2011 Dec;16(12):1177-88
pubmed: 21537331
J Neurosci. 2001 Mar 1;21(5):1635-44
pubmed: 11222654
J Cell Sci. 2009 Aug 15;122(Pt 16):2801-8
pubmed: 19795525
Arch Gen Psychiatry. 2000 Oct;57(10):925-35
pubmed: 11015810
Science. 2003 Aug 8;301(5634):805-9
pubmed: 12907793
Behav Neurosci. 2017 Feb;131(1):42-45
pubmed: 28004952
Biol Psychiatry. 2007 Jul 1;62(1):47-54
pubmed: 17123470
Proc Natl Acad Sci U S A. 2001 Oct 23;98(22):12796-801
pubmed: 11675510
J Neural Transm (Vienna). 2019 Nov;126(11):1383-1408
pubmed: 31584111
Neuropharmacology. 2019 Jul 15;153:98-110
pubmed: 31075295
Nature. 2011 Apr 28;472(7344):466-70
pubmed: 21460835
Mol Psychiatry. 2009 Aug;14(8):764-73, 739
pubmed: 18982002